Gastroparesis Drugs Market Report 2026

The gastroparesis drugs market size has grown strongly in recent years. It will grow from $5.7 billion in 2025 to $6.02 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to increasing diagnosis of diabetic gastroparesis, long-standing use of prokinetic and antiemetic drugs, growing prevalence of diabetes-related gastrointestinal disorders, availability of both otc and prescription symptom relief medications, expansion of gastroenterology care services.

The gastroparesis drugs market size is expected to see strong growth in the next few years. It will grow to $7.37 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to rising global diabetes prevalence, growing awareness of gastroparesis as a chronic condition, increasing demand for effective long-term symptom control, expansion of access to specialty gastrointestinal care, ongoing need for improved motility-enhancing therapies. Major trends in the forecast period include growing reliance on prokinetic agents for symptom management, increasing use of combination drug therapy for gastroparesis, rising demand for prescription-based gastroparesis treatments, expansion of symptom-focused treatment approaches, greater use of oral drug formulations for long-term management.

The rising prevalence of diabetes is expected to drive the growth of the gastroparesis drugs market in the coming years. Diabetes is a long-term metabolic condition marked by high blood glucose levels caused by inadequate insulin production or ineffective insulin use. The incidence of diabetes is increasing due to factors such as sedentary lifestyles, unhealthy eating habits, genetic susceptibility, urbanization, aging populations, and rising obesity levels. The gastroparesis drugs market supports diabetes management by offering medications that help alleviate symptoms such as nausea, vomiting, and delayed gastric emptying, which are common gastrointestinal complications associated with diabetic gastroparesis. For example, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the proportion of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while those with type 2 diabetes experienced a 21% increase. Additionally, the percentage of patients achieving target HbA1c levels rose to 37.9%, the highest figure ever recorded by the National Diabetes Audit. Therefore, the growing prevalence of diabetes is contributing to the expansion of the gastroparesis drugs market.

Major companies operating in the gastroparesis drugs market are concentrating on the development of innovative solutions, such as novel prokinetic therapies, to enhance gastric motility and reduce symptoms. Novel prokinetic therapies are newly developed medications intended to stimulate and improve the natural movement of the stomach and intestines, enabling food to pass more efficiently through the digestive system. For instance, in December 2023, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, received acceptance from the U.S. Food and Drug Administration (FDA) for the filing of its New Drug Application (NDA) for tradipitant for the treatment of gastroparesis symptoms. Tradipitant is an investigational oral neurokinin-1 receptor antagonist aimed at addressing gastroparesis, a serious digestive condition with significant unmet medical needs. This acceptance represents an important regulatory milestone for Vanda as it continues efforts to obtain marketing approval for tradipitant in gastroparesis patients.

In May 2025, Renexxion Ireland Ltd., an Ireland-based biopharmaceutical company, entered into a partnership with Dr. Falk Pharma GmbH to support the global development of naronapride for the treatment of gastroparesis. The collaboration is intended to complete the global Phase 2b MOVE-IT study and accelerate the development of naronapride as a potential best-in-class therapy for gastroparesis. Dr. Falk Pharma GmbH is a Germany-based company specializing in digestive and metabolic medicine.

Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastroparesis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the gastroparesis drugs market by increasing the cost of imported active pharmaceutical ingredients, intermediates, and formulation components used in both otc and prescription medications. These impacts have been most visible in prokinetic and antiemetic drug classes, particularly in North America and Europe where api sourcing is globally diversified. Asia-Pacific manufacturers have experienced pricing pressure due to trade-related supply dependencies. However, tariffs have encouraged domestic api production and local manufacturing of gastrointestinal drugs, supporting supply continuity and market stability.

The gastroparesis drugs market research report is one of a series of new reports that provides gastroparesis drugs market statistics, including gastroparesis drugs industry global market size, regional shares, competitors with a gastroparesis drugs market share, detailed gastroparesis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gastroparesis drugs industry. This gastroparesis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastroparesis drugs are medications used to treat and manage gastroparesis, a disorder in which the stomach empties its contents more slowly than normal, leading to symptoms such as nausea, vomiting, and abdominal pain. These medications commonly include prokinetic agents that enhance stomach motility, antiemetic drugs to reduce nausea and vomiting, and other therapies to manage pain and related symptoms.

The primary drug types for gastroparesis include over-the-counter (OTC) drugs and prescription drugs. Over-the-counter drugs are medicines that can be obtained without a healthcare provider’s prescription. These drugs are used to treat different disease types, including diabetic gastroparesis, post-surgical gastroparesis, idiopathic gastroparesis, and others, and are administered through various routes, mainly oral, injectable, and others. The drug categories include prokinetic agents, antiemetic drugs, proton pump inhibitors, and others, and they are distributed through hospitals, pharmacies, clinics, and e-commerce channels.

The gastroparesis drugs market consists of sales of metoclopramide, ondansetron, amitriptyline, and erythromycin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.